CLINICAL TRIALS PROFILE FOR IODINE POVACRYLEX; ISOPROPYL ALCOHOL

All Clinical Trials for IODINE POVACRYLEX; ISOPROPYL ALCOHOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04849455 ↗	Erector Spinae Plane Block Catheters and Intrathecal Morphine for Hepatic Resection	Recruiting	University of California, San Diego	Phase 4	2021-05-24	To determine whether the addition of erector spinae plane (ESP) catheters to existing multimodal analgesic regimen with intrathecal morphine provides superior postoperative analgesia in patients undergoing hepatic resection compared with patients not receiving ESP catheters.
NCT01233050 ↗	Efficacy Comparison of Two Preoperative Skin Antisepsis Preparations in Colorectal Surgery	Completed	3M	N/A	2010-12-01	Surgical site infections (SSI) are one of the most common complications in the post-operative patient, and the second most common health care associated infection overall. It is estimated that there are between 500 thousand and 1.1 million surgical site infections in the United States each year. Given the magnitude of the problem, prevention of surgical site infections is a major goal of peri-operative care. However, skin preparation prior to surgery has not been as rigorously examined. The primary objective of this study is to compare the efficacy of two FDA approved, popular peri-operative skin preparations 2% chlorhexidine gluconate / 70% isopropyl alcohol to Iodine Povacrylex [0.7% available Iodine] / 74% Isopropyl Alcohol in the prevention of superficial surgical site infection. Male and female patients, age 18 years and older undergoing elective colorectal surgical procedures involving a laparotomy will be enrolled. These patients are at high risk of SSI. Eligible patients will be assessed at regular intervals for SSI and characterization of bacterial pathogen(s) in patients with SSI. Patients will remain enrolled into the study until 35 days postoperatively.
NCT01233050 ↗	Efficacy Comparison of Two Preoperative Skin Antisepsis Preparations in Colorectal Surgery	Completed	University of Pennsylvania	N/A	2010-12-01	Surgical site infections (SSI) are one of the most common complications in the post-operative patient, and the second most common health care associated infection overall. It is estimated that there are between 500 thousand and 1.1 million surgical site infections in the United States each year. Given the magnitude of the problem, prevention of surgical site infections is a major goal of peri-operative care. However, skin preparation prior to surgery has not been as rigorously examined. The primary objective of this study is to compare the efficacy of two FDA approved, popular peri-operative skin preparations 2% chlorhexidine gluconate / 70% isopropyl alcohol to Iodine Povacrylex [0.7% available Iodine] / 74% Isopropyl Alcohol in the prevention of superficial surgical site infection. Male and female patients, age 18 years and older undergoing elective colorectal surgical procedures involving a laparotomy will be enrolled. These patients are at high risk of SSI. Eligible patients will be assessed at regular intervals for SSI and characterization of bacterial pathogen(s) in patients with SSI. Patients will remain enrolled into the study until 35 days postoperatively.

Clinical Trial Conditions for IODINE POVACRYLEX; ISOPROPYL ALCOHOL

Condition Name

Condition Name for IODINE POVACRYLEX; ISOPROPYL ALCOHOL
Intervention	Trials
Colorectal Surgery	1
Hepatic Resection	1
Acute Pain	1
Anesthesia	1

Condition MeSH

Condition MeSH for IODINE POVACRYLEX; ISOPROPYL ALCOHOL
Intervention	Trials
Acute Pain	1

Clinical Trial Locations for IODINE POVACRYLEX; ISOPROPYL ALCOHOL

Trials by Country

+

−

Trials by Country for IODINE POVACRYLEX; ISOPROPYL ALCOHOL
Location	Trials
United States	2

Trials by US State

+

−

Trials by US State for IODINE POVACRYLEX; ISOPROPYL ALCOHOL
Location	Trials
California	1
Pennsylvania	1

Clinical Trial Progress for IODINE POVACRYLEX; ISOPROPYL ALCOHOL

Clinical Trial Phase

Clinical Trial Phase for IODINE POVACRYLEX; ISOPROPYL ALCOHOL
Clinical Trial Phase	Trials
Phase 4	1
N/A	1

Clinical Trial Status

Clinical Trial Status for IODINE POVACRYLEX; ISOPROPYL ALCOHOL
Clinical Trial Phase	Trials
Completed	1
Recruiting	1

Clinical Trial Sponsors for IODINE POVACRYLEX; ISOPROPYL ALCOHOL

Sponsor Name

Sponsor Name for IODINE POVACRYLEX; ISOPROPYL ALCOHOL
Sponsor	Trials
3M	1
University of Pennsylvania	1
University of California, San Diego	1

Sponsor Type

Sponsor Type for IODINE POVACRYLEX; ISOPROPYL ALCOHOL
Sponsor	Trials
Other	2
Industry	1

Iodine Povacrylex and Isopropyl Alcohol: Clinical Trials, Market Analysis, and Projections

Introduction

Iodine povacrylex, often combined with isopropyl alcohol (IPA), is a potent antiseptic solution widely used in medical settings to prevent infections. This article delves into recent clinical trials, market analysis, and future projections for this critical antimicrobial agent.

Clinical Trials Update

Efficacy in Reducing Surgical-Site Infections

A large multicenter clinical trial conducted by the Program of Randomized Trials to Evaluate Preoperative Antiseptic Skin Solutions in Orthopedic Trauma (PREP-IT) has provided significant insights into the efficacy of iodine povacrylex in alcohol compared to chlorhexidine gluconate in alcohol. The study found that iodine povacrylex in 74% IPA resulted in fewer surgical-site infections in patients with closed fractures, with an infection rate of 2.4% compared to 3.3% for those treated with chlorhexidine gluconate in 70% IPA[3][4].

Specific Findings

• In patients with closed fractures, the use of iodine povacrylex in alcohol was associated with a lower incidence of surgical-site infections.
• For patients with open fractures, the infection rates were similar between the two antiseptics, indicating that iodine povacrylex is not harmful but may not offer additional benefits in these cases[3][4].

Expert Insights

Gerard Slobogean, MD, MPH, co-principal investigator of the study, emphasized that the results suggest iodine povacrylex in alcohol should be the preferred antiseptic for closed fracture surgery. He also suggested that these findings could be applicable to other surgical procedures such as arthroplasty, spine, or general surgeries[4].

Antimicrobial Performance

Broad-Spectrum Activity

Studies have shown that iodine povacrylex combined with IPA exhibits broad-spectrum antimicrobial activity. This solution is effective against a wide variety of microorganisms, including bacteria, viruses, fungi, and protozoa. In vitro tests demonstrated that both iodine povacrylex and povidone iodine (PVP-I) with IPA reduced microbial populations by 99.99% at contact times as short as 30 seconds[1].

Minimum Inhibitory Concentrations (MICs) and Minimum Bactericidal Concentrations (MBCs)

Both solutions showed MIC and MBC values at less than 1% of their full-strength concentrations, highlighting their potent antimicrobial properties[1].

Market Analysis

Global Market Size and Growth

The global povidone iodine market, which includes iodine povacrylex, was valued at $152.6 million in 2021 and is projected to reach $242.2 million by 2031, growing at a CAGR of 4.7% from 2022 to 2031. This growth is driven by increased awareness about hygiene and infection prevention, particularly in the healthcare sector[2].

Dominant Segments

• Topical Solution Segment: This segment dominated the market in 2021 and is expected to grow with a CAGR of 4.9% during the forecast period.
• Disinfectant Segment: This segment also holds a significant share, with a CAGR of 5.1% during the forecast period[2].

Regional Market

• Europe: Currently holds a dominant position in the market.
• Asia-Pacific: Projected to be the most lucrative region, growing at a CAGR of 5.3%[2].

Market Drivers and Restraints

Drivers

• Increased Demand for Antiseptics: The rising awareness about hospital-acquired infections and the need for effective antiseptics have driven the demand for iodine povacrylex and other povidone iodine products.
• COVID-19 Pandemic: The pandemic has increased the demand for instrument sterilization and skin antiseptics, further boosting the market[2].

Restraints

• Toxicity and Health Issues: Excessive consumption of iodine can lead to health issues, which may pose a restraint to market growth[5].

Future Projections

Growing Demand in Healthcare

The demand for iodine povacrylex is expected to continue growing due to its efficacy in reducing surgical-site infections and its broad-spectrum antimicrobial properties. The pharmaceutical industry's increasing need for antiseptics and disinfectants will also drive market growth[2].

Emerging Markets

The Asia-Pacific region is expected to witness the highest growth due to increasing healthcare expenditures and a rising awareness of infection prevention[2].

New Applications

The use of iodine povacrylex may expand beyond orthopedic trauma to other surgical procedures, such as arthroplasty, spine, and general surgeries, based on the positive outcomes from recent clinical trials[4].

Key Takeaways

• Clinical Efficacy: Iodine povacrylex in alcohol has been shown to reduce surgical-site infections in patients with closed fractures.
• Broad-Spectrum Activity: The solution exhibits potent antimicrobial activity against a wide range of microorganisms.
• Market Growth: The global povidone iodine market, including iodine povacrylex, is projected to grow at a CAGR of 4.7% from 2022 to 2031.
• Regional Dominance: Europe currently dominates the market, while the Asia-Pacific region is expected to be the most lucrative in the future.
• Market Drivers: Increased demand for antiseptics and the impact of the COVID-19 pandemic are key drivers of market growth.

FAQs

What is the primary use of iodine povacrylex in medical settings?

Iodine povacrylex is primarily used as a preoperative skin antiseptic to prevent surgical-site infections.

How does iodine povacrylex compare to chlorhexidine gluconate in reducing surgical-site infections?

Clinical trials have shown that iodine povacrylex in alcohol results in fewer surgical-site infections compared to chlorhexidine gluconate in alcohol for patients with closed fractures.

What is the projected growth rate of the global povidone iodine market?

The global povidone iodine market is projected to grow at a CAGR of 4.7% from 2022 to 2031.

Which region is expected to witness the highest growth in the povidone iodine market?

The Asia-Pacific region is expected to witness the highest growth, with a CAGR of 5.3%.

What are the main drivers of the povidone iodine market growth?

The main drivers include increased awareness about hygiene and infection prevention, and the impact of the COVID-19 pandemic on the demand for antiseptics and disinfectants.

Sources

1. Antimicrobial performance of two preoperative skin preparation solutions containing iodine and isopropyl alcohol. PubMed, 2021.
2. Povidone Iodine Market Size & Share | Forecast Report 2031. Allied Market Research.
3. Large Multicenter Clinical Trial Finds that Antiseptic Containing Iodine Reduces Surgical-Site Infections in Patients with Extremity Fractures. University of Maryland Medical Center, 2024.
4. VIDEO: Iodine povacrylex in alcohol preferred for antisepsis of closed fracture surgery. Healio, 2024.
5. Iodine Market Size & Share Analysis - Industry Research Report. Mordor Intelligence.